drugset / Trial / NCT06624371
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Phase 1
Recruiting
18 enrolled
Emory University
Morningside Foundation/Peach Bowl LegACy Fund · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG). The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.
Timeline
- Start
- 2025-03-28
- Primary completion
- 2027-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atovaquone | Small molecule | 30 mg/kg | Oral |
| Subject | Atovaquone | Small molecule | 750 mg | Oral |